Literature DB >> 16826581

The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer.

Stuart C Winter1, Ketan A Shah, Cheng Han, Leticia Campo, Helen Turley, Russell Leek, Rogan J Corbridge, Graham J Cox, Adrian L Harris.   

Abstract

BACKGROUND: Hypoxia promotes tumorigenesis through the hypoxia-inducible factor (HIF) pathway. There are 2 main homologues of the regulatory proteins, HIF-1alpha and HIF-2alpha, which have different effects in genetic knock-out experiments. Anemia may contribute to hypoxia by reducing oxygen delivery, but it is not known whether this influences HIF-alpha expression in tumors.
METHODS: The expression of HIF-1alpha, HIF-2alpha, carbonic anhydrase-9 (CA-9), and peripheral hemoglobin (Hb) levels in 151 patients who underwent surgery for head and neck squamous cell carcinoma (HNSCC) were analyzed and related to outcome.
RESULTS: High HIF-1alpha was expressed in 45 of 140 tumors (30%), HIF-2alpha was expressed in 21 of 139 tumors (14%), and CA-9 was expressed in 56 of 149 tumors (62%). There was a positive correlation between HIF-1alpha expression and HIF-2alpha expression (P =.0001). HIF-1alpha alone was associated with a worse disease-specific survival (DSS) (P =.05) and disease-free survival (DFS) (P = .03) in multivariate analyses. Nine percent of tumors expressed both high HIF-1alpha and high HIF-2alpha. High HIF-1alpha/high HIF-2alpha expression was an independent prognostic factors in DSS (P = .04) and DFS (P =.005) in multivariate analyses. There was no correlation noted between Hb and HIF-1alpha, HIF-2alpha, or CA-9.
CONCLUSIONS: HIF-1alpha alone was correlated with DSS and DFS. The additive effect of HIF-2alpha on poor prognosis suggested that different pathways may be regulated by HIF-2alph. Anemia that was not related to HIF-alpha expression suggests that tumor intrinsic factors regulate HIF-alpha therefore, anemia may be a surrogate marker for other factors that affect outcome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16826581     DOI: 10.1002/cncr.21983

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  38 in total

Review 1.  Molecular mechanisms of action and therapeutic uses of pharmacological inhibitors of HIF-prolyl 4-hydroxylases for treatment of ischemic diseases.

Authors:  Vaithinathan Selvaraju; Narasimham L Parinandi; Ram Sudheer Adluri; Joshua W Goldman; Naveed Hussain; Juan A Sanchez; Nilanjana Maulik
Journal:  Antioxid Redox Signal       Date:  2013-10-31       Impact factor: 8.401

2.  MiR-199a suppresses the hypoxia-induced proliferation of non-small cell lung cancer cells through targeting HIF1α.

Authors:  Gang Ding; Gang Huang; He-dai Liu; Hong-xiang Liang; Yu-feng Ni; Zhao-heng Ding; Guo-ying Ni; Hong-wei Hua
Journal:  Mol Cell Biochem       Date:  2013-12       Impact factor: 3.396

Review 3.  Correlation of expression of hypoxia-related proteins with prognosis in oral squamous cell carcinoma patients.

Authors:  A W Eckert; M Kappler; J Schubert; H Taubert
Journal:  Oral Maxillofac Surg       Date:  2012-05-17

Review 4.  Molecular responses to hypoxia-inducible factor 1α and beyond.

Authors:  Jason Brocato; Yana Chervona; Max Costa
Journal:  Mol Pharmacol       Date:  2014-02-25       Impact factor: 4.436

5.  Regulation of hypoxia-inducible genes by ETS1 transcription factor.

Authors:  Konstantin Salnikow; Olga Aprelikova; Sergey Ivanov; Sean Tackett; Monika Kaczmarek; Aldona Karaczyn; Herman Yee; Kazimierz S Kasprzak; John Niederhuber
Journal:  Carcinogenesis       Date:  2008-04-01       Impact factor: 4.944

Review 6.  Clinical biomarkers for hypoxia targeting.

Authors:  Quynh-Thu Le; Don Courter
Journal:  Cancer Metastasis Rev       Date:  2008-09       Impact factor: 9.264

Review 7.  The tumor microenvironment and metastatic disease.

Authors:  Sarah Jane Lunt; Naz Chaudary; Richard P Hill
Journal:  Clin Exp Metastasis       Date:  2008-06-10       Impact factor: 5.150

Review 8.  New developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia targeting.

Authors:  Nancy Y Lee; Quynh-Thu Le
Journal:  Semin Oncol       Date:  2008-06       Impact factor: 4.929

Review 9.  The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness.

Authors:  Bin Bao; Asfar S Azmi; Shadan Ali; Aamir Ahmad; Yiwei Li; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Biochim Biophys Acta       Date:  2012-05-10

Review 10.  The role of hypoxia-inducible factors in tumorigenesis.

Authors:  E B Rankin; A J Giaccia
Journal:  Cell Death Differ       Date:  2008-02-15       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.